About Solute carrier family 25 member 3
Solute carrier family 25 member 3 (SLC25A3) is a protein
from Homo sapiens identified by UniProt accession
Q00325, 362 residues long.
MolForge cross-references it against 0 known binders and
138 disease associations.
Target properties
| Protein name | Solute carrier family 25 member 3 |
| UniProt accession | Q00325 |
| Gene | SLC25A3 |
| Organism | Homo sapiens |
| Length | 362 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (138)
Diseases linked to this target (Open Targets).
- Cardiomyopathy - hypotonia - lactic acidosis · score 0.71
- cardiomyopathy-hypotonia-lactic acidosis syndrome · score 0.64
- neurodegenerative disease · score 0.54
- blood protein measurement · score 0.25
- mitochondrial disease · score 0.18
- smoking status measurement · score 0.14
- metabolite measurement · score 0.12
- pulse pressure measurement · score 0.10
- neuropathic pain · score 0.07
- lung adenocarcinoma · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q00325-F1 | alphafold | PREDICTED | 79.83 | — |
Amino-acid sequence (362 residues)
MFSSVAHLAR ANPFNTPHLQ LVHDGLGDLR SSSPGPTGQP RRPRNLAAAA VEEQYSCDYG SGRFFILCGL GGIISCGTTH TALVPLDLVK CRMQVDPQKY KGIFNGFSVT LKEDGVRGLA KGWAPTFLGY SMQGLCKFGF YEVFKVLYSN MLGEENTYLW RTSLYLAASA SAEFFADIAL APMEAAKVRI QTQPGYANTL RDAAPKMYKE EGLKAFYKGV APLWMRQIPY TMMKFACFER TVEALYKFVV PKPRSECSKP EQLVVTFVAG YIAGVFCAIV SHPADSVVSV LNKEKGSSAS LVLKRLGFKG VWKGLFARII MIGTLTALQW FIYDSVKVYF RLPRPPPPEM PESLKKKLGL TQ
Explore Solute carrier family 25 member 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets